NASDAQ:CMRX - Chimerix Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.00
  • Forecasted Upside: 41.77 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$9.17
▼ -1.11 (-10.80%)
1 month | 3 months | 12 months
Get New Chimerix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CMRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CMRX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$13.00
▲ +41.77% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Chimerix in the last 3 months. The average price target is $13.00, with a high forecast of $16.00 and a low forecast of $10.00. The average price target represents a 41.77% upside from the last price of $9.17.
Buy
The current consensus among 2 investment analysts is to buy stock in Chimerix. This rating has held steady since February 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/11/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/10/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/9/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/2/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/11/2021HC WainwrightBoost Price TargetBuy$7.00 ➝ $16.00High
i
1/8/2021JonestradingReiterated RatingBuy$10.00High
i
8/11/2020HC WainwrightReiterated RatingBuy$7.00High
i
Rating by E. White at HC Wainwright
2/26/2020HC WainwrightReiterated RatingBuy$7.00High
i
Rating by E. White at HC Wainwright
8/1/2019HC WainwrightBoost Price TargetBuy$5.00 ➝ $7.00Medium
i
Rating by E. White at HC Wainwright
5/9/2019CowenReiterated RatingHold$3.00High
i
3/6/2019CitigroupLower Price TargetNeutral ➝ Neutral$4.25 ➝ $2.00Low
i
2/6/2019HC WainwrightReiterated RatingBuyHigh
i
Rating by E. White at HC Wainwright
10/18/2018CowenReiterated RatingHold$6.00High
i
9/7/2018HC WainwrightReiterated RatingBuy$10.00High
i
6/7/2018HC WainwrightReiterated RatingBuy$10.00Low
i
Rating by E. White at HC Wainwright
3/19/2018HC WainwrightReiterated RatingBuy$10.00Low
i
Rating by E. White at HC Wainwright
3/1/2018CowenReiterated RatingHold$6.00Low
i
2/14/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightLow
i
2/2/2018HC WainwrightInitiated CoverageBuy ➝ Buy$10.00Low
i
Rating by E. White at HC Wainwright
5/1/2017(FBRC)Reiterated RatingHold$7.00High
i
Rating by Edward White at (FBRC)
4/28/2017CowenReiterated RatingHold$6.00Low
i
3/4/2017(FBRC)Set Price TargetHold$8.00N/A
i
Rating by Edward White at (FBRC)
2/22/2017(FBRC)Reiterated RatingHoldN/A
i
Rating by Edward White at (FBRC)
1/11/2017(FBRC)Reiterated RatingHold$8.00N/A
i
Rating by Edward White at (FBRC)
10/30/2016(FBRC)Reiterated RatingHoldN/A
i
Rating by Edward White at (FBRC)
8/18/2016Piper Jaffray CompaniesSet Price TargetBuy$12.00N/A
i
Rating by joshua schimmer at Piper Jaffray Companies
8/9/2016JPMorgan Chase & Co.Reiterated RatingHold$7.00N/A
i
8/9/2016(FBRC)Lower Price TargetMkt Perform$9.00 ➝ $8.00N/A
i
Rating by Edward White at (FBRC)
7/17/2016(FBRC)Reiterated RatingHoldN/A
i
Rating by Edward White at (FBRC)
5/10/2016(FBRC)Reiterated RatingHoldN/A
i
Rating by Edward White at (FBRC)
(Data available from 3/4/2016 forward)
Chimerix logo
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $9.17
$9.00
$10.54

50 Day Range

MA: $9.46
$7.94
$11.25

52 Week Range

Now: $9.17
$1.19
$11.57

Volume

928,881 shs

Average Volume

1,429,029 shs

Market Capitalization

$574.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Chimerix?

The following Wall Street research analysts have issued research reports on Chimerix in the last year: HC Wainwright, Jonestrading, and Zacks Investment Research.
View the latest analyst ratings for CMRX.

What is the current price target for Chimerix?

2 Wall Street analysts have set twelve-month price targets for Chimerix in the last year. Their average twelve-month price target is $13.00, suggesting a possible upside of 41.8%. HC Wainwright has the highest price target set, predicting CMRX will reach $16.00 in the next twelve months. Jonestrading has the lowest price target set, forecasting a price of $10.00 for Chimerix in the next year.
View the latest price targets for CMRX.

What is the current consensus analyst rating for Chimerix?

Chimerix currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CMRX will outperform the market and that investors should add to their positions of Chimerix.
View the latest ratings for CMRX.

What other companies compete with Chimerix?

How do I contact Chimerix's investor relations team?

Chimerix's physical mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company's listed phone number is 919-806-1074 and its investor relations email address is [email protected] The official website for Chimerix is www.chimerix.com.